CDTX Overview

Constellation Brands Options Activity: Constellation Brands Inc (STZ) has seen a trading volume of 14,009 options contracts today, representing about 1.4 million underlying shares, which is 57.3% of its average daily trading volume over the past month. Notably, the $115 strike put option expiring January 30, 2026, has recorded 2,505 contracts traded.

Lam Research Options Activity: Lam Research Corp (LRCX) has reported a higher options volume of 59,750 contracts today, equating to approximately 6.0 million underlying shares, or 56.2% of its average daily trading volume. The $167.50 strike call option expiring December 19, 2025, has seen significant activity with 3,648 contracts traded.

Options Trading Insights: The article provides insights into the options trading activities of STZ and LRCX, highlighting specific strike prices and expiration dates that have garnered notable trading volumes.

Source Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

ABIVAX Société Anonyme: The biotechnology company reached the $100 mark on October 30, 2025, driven by its lead drug candidate, Obefazimod, which is in a pivotal phase III trial for ulcerative colitis. The stock rose from $7.83 in July 2025 to an all-time high of $138.49 in December 2025.

Nutex Health Inc.: This healthcare services company crossed the $100 threshold on April 9, 2025, reflecting significant revenue growth and profitability, with total revenue of $723.6 million for the first nine months of 2025. The stock increased from $33.56 in November 2024 to a peak of $193 in December 2025.

Cidara Therapeutics Inc.: Cidara reached the $100 milestone on October 1, 2025, following its agreement to be acquired by Merck for $221.50 per share. The stock price rose from $18.98 in November 2024, highlighting its growth potential in preventive influenza therapy.

Palvella Therapeutics Inc.: The company, focused on rare diseases, hit the $100 mark on November 24, 2025, after announcing positive results from its phase 2 study. The stock climbed from $25 in March 2025 to a peak of $112 in December 2025, reflecting investor confidence in its ongoing trials.